Captisol®: What gives EuropeanPharmacopeia?!

Analytical Method Challenges for EP Monograph, Captisol ® At the 2023 American Drug Delivery and Formulation Summit, Ryan Memmer from Singota Solutions (leading CDMO in Bloomington, Indiana), captivated the audience with his insightful presentation on "Analytical Method Challenges for EP Monograph," titled "Captisol®: What gives European Pharmacopeia?!" Memmer's expertise in…

Specializing In Small And Early-Stage Injectables, Not Just Small Batches

Source: Singota Solutions Navigating the complex landscape of pharmaceutical development (Injectables), particularly for small and early-stage companies, demands careful consideration of manufacturing partnerships. While large CDMOs may seem like obvious choices, their focus on high-volume production often leaves smaller projects sidelined. This shift is notable in the context of the industry's…

Analysis Paralysis: Navigating Early-Phase Analytical Validation

Significant confusion persists across the pharmaceutical/biopharmaceutical industry relevant to early-phase analytical development and analytical validation. While several guidance documents serve as a de facto standard, distinguishing method validation requirements from suggestions, when and how to apply those guidelines often is not a straightforward task.It is critical to establish a product/project’s…

Keys To Successful Blinded Labeling

Blinded labeling is an essential element in all clinical trials. To remove the risk of bias, active pharmaceutical ingredient (API) drugs, delivery apparatus, and kits must be visually indistinguishable from placebo units — including their respective labels. The content and creation of these labels, though, is tightly regulated and benefits…

Strengthen Your IND Submission To The FDA By Conducting Microbial Challenge Studies

Microbial challenge studies are becoming increasingly common as drug products (DP) are being manufactured with different types of active pharmaceutical ingredients (API) than fifteen years ago (IND Submission). Peptides, proteins, monoclonal antibodies, oligonucleotides, and biosimilars are more common; manufacturing no longer places an emphasis on small molecules. These new APIs…

Posts pagination